WO2014187343A1 - Dérivé benzofurane, son procédé de préparation, et son application médicale - Google Patents

Dérivé benzofurane, son procédé de préparation, et son application médicale Download PDF

Info

Publication number
WO2014187343A1
WO2014187343A1 PCT/CN2014/078156 CN2014078156W WO2014187343A1 WO 2014187343 A1 WO2014187343 A1 WO 2014187343A1 CN 2014078156 W CN2014078156 W CN 2014078156W WO 2014187343 A1 WO2014187343 A1 WO 2014187343A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
fluorenyl
compound
formula
salt
Prior art date
Application number
PCT/CN2014/078156
Other languages
English (en)
Chinese (zh)
Inventor
张晨
王健民
何平
雷鸣
叶飞
魏用刚
邓炳初
Original Assignee
四川海思科制药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 四川海思科制药有限公司 filed Critical 四川海思科制药有限公司
Priority to CN201480003531.4A priority Critical patent/CN104870429B/zh
Publication of WO2014187343A1 publication Critical patent/WO2014187343A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms

Abstract

La présente invention concerne un dérivé benzofurane, son procédé de préparation, et son application médicale, et concerne plus particulièrement un composé représenté par la formule générale (I), un stéréoisomère associé, un hydrate associé, un solvate associé, un composé eutectique associé, un sel ou promédicament associé pharmaceutiquement acceptable, son procédé de préparation, une composition pharmaceutique comprenant ledit dérivé benzofurane, et une application médicale dudit composé ou de ladite composition pharmaceutique, en particulier comme agoniste du récepteur GPR40 (récepteur couplé à la protéine G), les définitions des groupes substituants dans la formule générale (I) étant identiques aux définitions données dans la description.
PCT/CN2014/078156 2013-05-22 2014-05-22 Dérivé benzofurane, son procédé de préparation, et son application médicale WO2014187343A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201480003531.4A CN104870429B (zh) 2013-05-22 2014-05-22 苯并呋喃衍生物、其制备方法及其在医药上的应用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310192084 2013-05-22
CN201310192084.9 2013-05-22

Publications (1)

Publication Number Publication Date
WO2014187343A1 true WO2014187343A1 (fr) 2014-11-27

Family

ID=51932901

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2014/078156 WO2014187343A1 (fr) 2013-05-22 2014-05-22 Dérivé benzofurane, son procédé de préparation, et son application médicale

Country Status (2)

Country Link
CN (1) CN104870429B (fr)
WO (1) WO2014187343A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107540648A (zh) * 2017-08-09 2018-01-05 江苏工程职业技术学院 一种达格列净的制备方法
WO2018113800A1 (fr) * 2016-12-22 2018-06-28 上海宣创生物科技有限公司 Sel de glycine bétaïne de pyrroloquinoléine quinone
US10710986B2 (en) 2018-02-13 2020-07-14 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10774071B2 (en) 2018-07-13 2020-09-15 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
CN112641776A (zh) * 2019-10-12 2021-04-13 江苏晶立信医药科技有限公司 一种以二甲双胍或其可药用盐和澳格列汀或其可药用盐为活性成分的药用组合物
CN113717135A (zh) * 2021-01-07 2021-11-30 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 羰基取代的苯并二氢呋喃、苯并二氢吡喃化合物的合成方法
CN113912592A (zh) * 2021-11-03 2022-01-11 西北农林科技大学 一种和厚朴酚并二氢呋喃酯类衍生物、制备方法及其应用
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11279702B2 (en) 2020-05-19 2022-03-22 Kallyope, Inc. AMPK activators
CN114262250A (zh) * 2021-12-24 2022-04-01 乐威医药（江苏）股份有限公司 芳香环苄基邻位双烷基的合成方法
US11407768B2 (en) 2020-06-26 2022-08-09 Kallyope, Inc. AMPK activators
US11512065B2 (en) 2019-10-07 2022-11-29 Kallyope, Inc. GPR119 agonists

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110294744A (zh) * 2018-03-21 2019-10-01 中国医学科学院药物研究所 Gpr40受体激动剂、其制法和其药物组合物与用途
WO2019179494A1 (fr) * 2018-03-23 2019-09-26 深圳市塔吉瑞生物医药有限公司 Composé d'acide pentadécanedioïque substitué, composition pharmaceutique et utilisation associée
CN113671048A (zh) * 2020-05-13 2021-11-19 昆药集团股份有限公司 一种高哌嗪残留物中对甲苯磺酸甲酯和对甲苯磺酸乙酯的检测方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1882563A (zh) * 2003-11-20 2006-12-20 默克专利有限公司 包含苯并呋喃和苯并噻吩衍生物的抗糖尿病化合物
CN103524466A (zh) * 2012-07-03 2014-01-22 上海昀怡健康管理咨询有限公司 二氢苯并呋喃类衍生物、其制备方法、中间体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1630152A4 (fr) * 2003-05-30 2009-09-23 Takeda Pharmaceutical Compose cyclique condense
RS52307B (en) * 2006-06-27 2012-12-31 Takeda Pharmaceutical Company Limited CONDENSED CYCLIC UNITS
EP2440541A1 (fr) * 2009-06-09 2012-04-18 Takeda Pharmaceutical Company Limited Nouveau composé cyclique fondu et son utilisation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1882563A (zh) * 2003-11-20 2006-12-20 默克专利有限公司 包含苯并呋喃和苯并噻吩衍生物的抗糖尿病化合物
CN103524466A (zh) * 2012-07-03 2014-01-22 上海昀怡健康管理咨询有限公司 二氢苯并呋喃类衍生物、其制备方法、中间体及其应用

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018113800A1 (fr) * 2016-12-22 2018-06-28 上海宣创生物科技有限公司 Sel de glycine bétaïne de pyrroloquinoléine quinone
CN107540648A (zh) * 2017-08-09 2018-01-05 江苏工程职业技术学院 一种达格列净的制备方法
US10710986B2 (en) 2018-02-13 2020-07-14 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11555029B2 (en) 2018-02-13 2023-01-17 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10774071B2 (en) 2018-07-13 2020-09-15 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11512065B2 (en) 2019-10-07 2022-11-29 Kallyope, Inc. GPR119 agonists
CN112641776A (zh) * 2019-10-12 2021-04-13 江苏晶立信医药科技有限公司 一种以二甲双胍或其可药用盐和澳格列汀或其可药用盐为活性成分的药用组合物
US11279702B2 (en) 2020-05-19 2022-03-22 Kallyope, Inc. AMPK activators
US11851429B2 (en) 2020-05-19 2023-12-26 Kallyope, Inc. AMPK activators
US11407768B2 (en) 2020-06-26 2022-08-09 Kallyope, Inc. AMPK activators
CN113717135A (zh) * 2021-01-07 2021-11-30 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 羰基取代的苯并二氢呋喃、苯并二氢吡喃化合物的合成方法
CN113912592A (zh) * 2021-11-03 2022-01-11 西北农林科技大学 一种和厚朴酚并二氢呋喃酯类衍生物、制备方法及其应用
CN114262250A (zh) * 2021-12-24 2022-04-01 乐威医药（江苏）股份有限公司 芳香环苄基邻位双烷基的合成方法

Also Published As

Publication number Publication date
CN104870429A (zh) 2015-08-26
CN104870429B (zh) 2017-05-03

Similar Documents

Publication Publication Date Title
WO2014187343A1 (fr) Dérivé benzofurane, son procédé de préparation, et son application médicale
WO2015000412A1 (fr) Dérivé benzocyclobutène et procédé de préparation et application pharmaceutique associée
TWI374141B (en) Spiro-oxindole compounds and their uses as therapeutic agents
AU2014221489B2 (en) Tricyclic compound and use thereof
TWI531571B (zh) 六氫茚并吡啶及八氫苯并喹啉之芳基－及雜芳基羰基衍生物
JP5465658B2 (ja) 複素環化合物
JP5450083B2 (ja) 複素環化合物
JP6106179B2 (ja) 芳香環化合物
AU756965B2 (en) Benzofurylpyrone derivatives
TW201103535A (en) Carboxylic acid compounds
MX2011006904A (es) Compuesto heterociclico biciclico novedoso.
BRPI0817843B1 (pt) inibidores da quinase c-fms, composição farmacêutica que os compreende e processo para a fabricação da dita composição
WO2014036897A1 (fr) Dérivés d'imidazoline, leurs procédés de préparation et leurs applications en médecine
KR20160078286A (ko) Gpr120 효능제로서의 바이아릴 유도체
WO2013104257A1 (fr) Dérivés polycycliques, leur procédé de préparation et leurs utilisations médicales
WO2019205983A1 (fr) Composé oxa-spiro, son procédé de préparation et ses utilisations
KR20170063937A (ko) 제2형 당뇨병 치료용 gpr40 작용제로서의 치환된 벤조티오페닐 유도체
WO2015010655A1 (fr) Dérivés d'acides carboxyliques cycliques condensés triadiques, procédé de préparation correspondant et utilisation pharmaceutique correspondante
AU2012367780B2 (en) Derivatives of aza adamantane and uses thereof
WO2015032328A1 (fr) Dérivé indane, son procédé de préparation, et son application pharmaceutique
EA031766B1 (ru) Ингибиторы альдостеронсинтазы
US20240101512A1 (en) Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds and Their Derivatives, Processes for Their Preparation and Therapeutic Uses Thereof
US20230357220A1 (en) 3-((1h-pyrazol-4-yl)methyl)-6′-(phenyl)-2h-(1,2′-bipyridin)-2-one derivatives and related compounds as gpr139 antagonists for use in a method of treatment of e.g. depression
EP4153583A1 (fr) Dérivés de 1-((1h-pyrazol-4-yl)méthyl)-3-(phényl)-1,3-dihydro-2h-imidazol-2-one et composés apparentés servant d'antagonistes de gpr139 pour le traitement de la dépression, par exemple
JP2000128878A (ja) ベンゾフリル−α−ピリドン誘導体

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14801631

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14801631

Country of ref document: EP

Kind code of ref document: A1